Progress towards the development of new vaccines against whooping cough
Authors:
- Audino PoddaAPAudino Podda
- Luciano NencioniLNLuciano Nencioni
- 31 December 1992
- Vol. 10 (14) , 1027-1032
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: Safety and immunogenicity in 12- to 24- and 2- to 4-month-old childrenThe Journal of Pediatrics, 1992
- Effect of Pertussis Toxin on Susceptibility of Infant Rats to Haemophilus influenzae Type bThe Journal of Infectious Diseases, 1992
- Pertussis hospitalizations and mortality in the United States, 1985-1988. Evaluation of the completeness of national reporting1992
- Seroepidemiology of Pertussis in ItalyClinical Infectious Diseases, 1991
- Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDaVaccine, 1991
- Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G.Journal of Experimental Medicine, 1990
- Haemophilus influenzae infections and whooping coughThe Lancet, 1990
- The efficacy of acellular pertussis vaccine1989
- Mapping of a Protective Epitope of Pertussis Toxin by In Vitro Refolding of Recombinant FragmentsNature Biotechnology, 1988
- Pertussis Toxin and Extracytoplasmic Adenylate Cyclase as Virulence Factors of Bordetella pertussisThe Journal of Infectious Diseases, 1984